Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors in the central nervous program, conolidine modulates alternate molecular targets. A Science Advancements study located that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By influen... https://julioj395duj0.blogdeazar.com/profile